London Daily

Focus on the big picture.
Thursday, Jul 10, 2025

What do we know about the Russian vaccine

What do we know about the Russian vaccine

Study findings on the Russian vaccine against Covid-19 show that it is safe, well tolerated and induces cellular immune responses in 100% of healthy participants.

This was published by The Lancet magazine, based on a preliminary study carried out by researchers from the Russian government. This study was evaluated by a rereading committee of the British medical journal prior to its publication.

All reported adverse events on the Russian vaccine were mostly mild. However, a comparative clinical study with other vaccines is needed to confirm these findings, the publication notes.


The information is released after the Russian authorities announced, last August, their vaccine against Covid-19, which they call Sputnik V, in honor of the first satellite launched into space, in 1957.

On August 11, it was reported that Sputnik V was entering the third and final phase of clinical trials.

What elements emerge from the article published in The Lancet? Sputnik V consists of two components: recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5); and that both rAd26 and rAd5 contain the SARS-CoV-2 virus protein S gene.

It should be explained that adenoviruses are a group of viruses that typically cause respiratory diseases, such as colds, conjunctivitis (eye infection), bronchiolitis, pneumonia, among others. Both components were developed, manufactured and stored by the National Research Center for Epidemiology and Microbiology NF Gamaleya (Moscow).

During vaccination, component 1 is introduced for the first time and, after three weeks, component 2. According to the evaluation of the developer, the immunity can last up to two years. Then you may need to vaccinate again. However, this remains to be explored in post-marketing studies, explained Vadim Tarasov, director of the Institute of Transmission Medicine and Biotechnology and head of the department of pharmacology at Ivan Sechenov University.

How were the studies done?

It was precisely at the Ivan Sechenov University that preclinical trials of two dosage forms of the Russian vaccine were carried out. The other place where the studies took place was at Burdenko Hospital.

Healthy adult volunteers (men and women), whose ages ranged from 18 to 60 years old, were enrolled for the Russian vaccine studies. Between June 18 and August 3, 2020, they enrolled 76 participants in the two studies Thus, in each study, 38 volunteers were vaccinated. More men than women participated in the study.

According to Tarasov, the study itself was carried out in two stages. One of them was the observation of volunteers for 14 days in isolation to prevent them from contracting the coronavirus infection. Once the observation was completed and it was confirmed that the volunteers did not have Covid-19, they were transported, with all possible precautions, to the cardioangiology center of the Ivan Sechenov University.

In this hospital, 38 volunteers stayed 28 days after the first injection of the drug and were discharged one week after the second. Their stay in the hospital was organized to protect them from the possibility of becoming infected and thus dropping out of the study or entering incorrect data on the immunity developed, he explained.

It was extremely important work, to reliably assess the response of the immune system and draw preliminary conclusions about the effectiveness of the drug, says Sechenov.

According to the study published in The Lancet, the most common reactions among participants were pain at the injection site, hyperthermia (body temperature 37–38 ° C), headache, fatigue, and muscle and joint pain. No serious adverse events were reported during the investigation.

Notably, the volunteers had no infectious diseases at the time of vaccination and for 14 days prior to vaccination, and did not receive any other vaccines within 30 days of participating in the study.

Caution

When the world announcement of Sputnik V was made, it was greeted with skepticism by many researchers by the scientific community. Its efficacy and safety were questioned, mainly due to the absence of public data on the trials conducted up to that point.

This opinion is largely due to misunderstanding that the preparation in question is registered in the Russian Federation 'conditionally', says Sechenov. As he explains, this is a well-known and widely used mechanism in the United States, the European Union, Japan and other countries with a developed regulatory system. Its essence lies in the fact that if it is necessary to put the drug into practice as soon as possible, for example, for orphan or oncological diseases, during epidemics, etc., and it is impossible to conduct full clinical trials, the drug is temporarily registered with indications of limited use, which are based on the results of clinical trials already carried out, he details.

At the same time, a mandatory requirement is to conduct post-registration studies with the participation of a certain number of patients at a given time, and any use of the drug becomes part of the study.

This is the case of the Sputnik V vaccine, whose registration certificate was issued until January 2021, and as a prerequisite, clinical trials with 40,000 participants were established, says Sechenov.

As has been announced, this will be the objective of the phase 3 trial (which will include 40,000 participants), of various ages and with different risk levels.

Since the announcement made by President Vladimir Putin last August, the World Health Organization (WHO) has urged Russia to follow the established protocol and comply with all the phases necessary to develop a safe vaccine.

The WHO will not endorse a vaccine against the coronavirus if it is not safe and effective, declared this Friday, September 4, its director general, Tedros Adhanom Ghebreyesus.

According to the WHO, there are 176 vaccine projects underway in the world, of which 34 are in the clinical trial phase, which means that they have started to be tested in humans. Among these, eight are in phase three, the most advanced.

Around the world, the pandemic has claimed so far the lives of more than 875,700 people and infected more than 26.6 million.


Newsletter

Related Articles

0:00
0:00
Close
Severe Heatwave Claims 2,300 Lives Across Europe
NVIDIA Achieves Historic Milestone as First Company Valued at $4 Trillion
Declining Beer Consumption Signals Cultural Shift in Germany
Linda Yaccarino Steps Down as CEO of X After Two Years
US Imposes New Tariffs on Brazilian Exports Amid Political Tensions
Azerbaijan and Armenia are on the brink of a historic peace deal.
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Weinstein Victim’s Lawyer Says MeToo Movement Still Strong
U.S. Enacts Sweeping Tax and Spending Legislation Amid Trade Policy Shifts
Football Mourns as Diogo Jota and Brother André Silva Laid to Rest in Portugal
Labour Expected to Withdraw Support for Special Needs Funding Model
Leaked Audio Reveals Tory Aide Defending DEI Record
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
London Stock Exchange Faces Historic Low in Initial Public Offerings
A new online platform has emerged in the United Kingdom, specifically targeting Muslim men seeking virgin brides
Trump Celebrates Independence Day with B-2 Flyover and Signs Controversial Legislation
Boris Johnson Urges Conservatives to Ignore Farage
SNP Ordered to Update Single-Sex Space Guidance Within Days
Starmer Set to Reject Calls for Wealth Taxes
Stolen Century-Old Rolls-Royce Recovered After Hotel Theft
Macron Presses Starmer to Recognise Palestinian State
Labour Delayed Palestine Action Ban Over Riot Concerns
Swinney’s Tax Comments ‘Offensive to Scots’, Say Tories
High Street Retailers to Enforce Bans on Serial Shoplifters
Music Banned by Henry VIII to Be Performed After 500 Years
Steve Coogan Says Working Class Is Being ‘Ethnically Cleansed’
Home Office Admits Uncertainty Over Visa Overstayer Numbers
JD Vance Questions Mandelson Over Reform Party’s Rising Popularity
Macron to Receive Windsor Carriage Ride in Royal Gesture
Labour Accused of ‘Hammering’ Scots During First Year in Power
BBC Head of Music Stood Down Amid Bob Vylan Controversy
Corbyn Eyes Hard-Left Challenge to Starmer’s Leadership
London Tube Trains Suspended After Major Fire Erupts Nearby
Richard Kemp: I Felt Safer in Israel Under Attack Than in the UK
Cyclist Says Police Cited Human Rights Act for Riding No-Handed
China’s Central Bank Consults European Peers on Low-Rate Strategies
AI Raises Alarms Over Long-Term Job Security
Saudi Arabia Maintains Ties with Iran Despite Israel Conflict
Musk Battles to Protect Tesla Amid Trump Policy Threats
Air France-KLM Acquires Majority Stake in Scandinavian Airlines
UK Educators Sound Alarm on Declining Child Literacy
Shein Fined €40 Million in France Over Misleading Discounts
Brazil’s Lula Visits Kirchner During Argentina House Arrest
Trump Scores Legislative Win as House Passes Tax Reform Bill
Keir Starmer Faces Criticism After Rocky First Year in Power
DJI Launches Heavy-Duty Coaxial Quadcopter with 80 kg Lift Capacity
U.S. Senate Approves Major Legislation Dubbed the 'Big Beautiful Bill'
Largest Healthcare Fraud Takedown in U.S. History Announced by DOJ
×